HomeCompareDMTTF vs MRK

DMTTF vs MRK: Dividend Comparison 2026

DMTTF yields 1790.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTTF wins by $3560995371.95M in total portfolio value
10 years
DMTTF
DMTTF
● Live price
1790.51%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3560995372.00M
Annual income
$3,208,492,995,096,889.00
Full DMTTF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — DMTTF vs MRK

📍 DMTTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTTFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTTF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTTF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTTF
Annual income on $10K today (after 15% tax)
$152,193.38/yr
After 10yr DRIP, annual income (after tax)
$2,727,219,045,832,355.50/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, DMTTF beats the other by $2,727,219,045,824,027.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTTF + MRK for your $10,000?

DMTTF: 50%MRK: 50%
100% MRK50/50100% DMTTF
Portfolio after 10yr
$1780497686.03M
Annual income
$1,604,246,497,553,343.50/yr
Blended yield
90.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DMTTF
No analyst data
Altman Z
-0.2
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTTF buys
0
MRK buys
0
No recent congressional trades found for DMTTF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTTFMRK
Forward yield1790.51%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3560995372.00M$56.8K
Annual income after 10y$3,208,492,995,096,889.00$9,798.13
Total dividends collected$3535749756.14M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DMTTF vs MRK ($10,000, DRIP)

YearDMTTF PortfolioDMTTF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$189,751$179,051.03$11,206$366.19+$178.5KDMTTF
2$3,378,278$3,175,244.60$12,650$502.35+$3.37MDMTTF
3$56,447,685$52,832,927.74$14,407$694.19+$56.43MDMTTF
4$885,432,609$825,033,585.64$16,585$967.82+$885.42MDMTTF
5$13,042,172,033$12,094,759,140.97$19,342$1,363.89+$13042.15MDMTTF
6$180,452,678,412$166,497,554,336.98$22,913$1,947.19+$180452.66MDMTTF
7$2,346,051,940,236$2,152,967,574,335.48$27,662$2,823.89+$2346051.91MDMTTF
8$28,669,689,008,997$26,159,413,432,944.53$34,159$4,173.35+$28669688.97MDMTTF
9$329,441,473,744,276$298,764,906,504,648.75$43,337$6,308.80+$329441473.70MDMTTF
10$3,560,995,372,003,264$3,208,492,995,096,889.00$56,776$9,798.13+$3560995371.95MDMTTF

DMTTF vs MRK: Complete Analysis 2026

DMTTFStock

Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.

Full DMTTF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this DMTTF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTTF vs SCHDDMTTF vs JEPIDMTTF vs ODMTTF vs KODMTTF vs MAINDMTTF vs JNJDMTTF vs ABBVDMTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.